EUVIMEDEUVIMED entdecken
Crossref

Session 5: Protein Degraders

Kiran Palyada iD, Renee Hukkanen iD, Stephanie Leuenroth-Quinn, Allison Vitsky iD, Richard Peterson, Katie Stamp, Clare Hoover, Laurie Volak

Toxicologic Pathology · 2024-12 · 52 (8) · 553-565

DOI: 10.1177/01926233241300452 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxicologic Pathology, online erschienen am 11.12.2024. Verfasst von Kiran Palyada und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc., La Jolla, California, USA. Hauptthemen laut MEDLINE: Proteolysis, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The so-called undruggable space is an exciting area of potential growth for drug development. Undruggable proteins are defined as those unable to be targeted via conventional small molecule drugs. New modalities are being developed to potentially target these proteins. Targeted protein degradation (TPD) is one such new modality, which over the last two decades has moved from academia to industry. TPD makes use of the endogenous degradation machinery present in all cells, in which E3 ubiquitin ligases mark proteins for degradation via ubiquitin attachment. This session explored the challenges and perspectives of using protein degraders as novel therapeutic agents. The session began with a general introduction to the modality, followed by considerations in evaluating their on- and off-target toxicities including data from an IQ Consortium working group survey. Unique absorption, distribution, metabolism, and excretion (ADME) properties of degrader molecules were presented in relation to their effect on drug development and nonclinical safety assessment. The role of transgenic models in evaluating hemotoxicity associated with cereblon-based therapies was then discussed. A case study to derisk dose-limiting thrombocytopenia was also presented. Finally, a regulatory perspective on the challenges of having toxicity associated with protein degraders was presented.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteolysisUbiquitin-Protein LigasesAnimalsHumansDrug DevelopmentCongresses as Topic

Stichwörter der Autor:innen

E3 ligasePROTACVHLcereblonheterobifunctional moleculesmolecular gluesprotein degraders

Substanzen

Ubiquitin-Protein Ligases

Autor:innen und Institutionen

  • Pfizer Inc., La Jolla, California, USA.
  • Amgen, Cambridge, Massachusetts, USA.
  • U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • AbbVie, North Chicago, Illinois, USA.
  • Bristol Myers Squibb, Summit, New Jersey, USA.
  • AstraZeneca, Waltham, Massachusetts, USA.

ORCID-Profile: Kiran Palyada, Renee Hukkanen, Allison Vitsky

Zitieren

APA

Palyada, K., Hukkanen, R., Leuenroth-Quinn, S., Vitsky, A., Peterson, R., Stamp, K., Hoover, C., & Volak, L. (2024). Session 5: Protein Degraders. Toxicologic Pathology, 52(8), 553-565. https://doi.org/10.1177/01926233241300452

Vancouver

Palyada K, Hukkanen R, Leuenroth-Quinn S, Vitsky A, Peterson R, Stamp K, et al. Session 5: Protein Degraders. Toxicologic Pathology. 2024;52(8):553-565. doi:10.1177/01926233241300452

BibTeX
@article{Palyada2024,
  author = {Palyada, Kiran and Hukkanen, Renee and Leuenroth-Quinn, Stephanie and Vitsky, Allison and Peterson, Richard and Stamp, Katie and Hoover, Clare and Volak, Laurie},
  title = {Session 5: Protein Degraders},
  journal = {Toxicologic Pathology},
  year = {2024},
  volume = {52},
  number = {8},
  pages = {553--565},
  doi = {10.1177/01926233241300452}
}
Kostenlos starten →